Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 543Squamous Cell Carcinoma of Head and Neck 280Head and Neck Neoplasms 257Lung Neoplasms 240Uterine Cervical Neoplasms 180Stomach Neoplasms 172Esophageal Neoplasms 161Nasopharyngeal Carcinoma 127Urinary Bladder Neoplasms 117Neoplasms 115Esophageal Squamous Cell Carcinoma 115Small Cell Lung Carcinoma 105Ovarian Neoplasms 92Breast Neoplasms 92Neoplasm Metastasis 89Cholangiocarcinoma 76Carcinoma, Squamous Cell 76Pancreatic Neoplasms 72Biliary Tract Neoplasms 71Oropharyngeal Neoplasms 57Mesothelioma, Malignant 57Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 46Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Gallbladder Neoplasms 39

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Radiosurgery 2Paclitaxel 2Doxorubicin 2Bevacizumab 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Disease Progression × Cisplatin × Clear all
NCT05712356 2026-05-26

BOLSTER

Lisata Therapeutics, Inc.

Phase 2 Terminated
66 enrolled 12 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT07274384 2025-12-10

HYPERBOLIC

Università Vita-Salute San Raffaele

Phase 2 Not yet recruiting
74 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07008716 2025-06-06

Omitting CTV for Primary Tumor in LS-SCLC

Sun Yat-sen University

Phase 3 Recruiting
852 enrolled

Radiation Injuries, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡